BeiGene Ltd. Sponsored ADR Stock

$222.91

0.21%

Nasdaq, Tue, Feb 04 2025

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BeiGene Ltd. Sponsored ADR Stock price

$222.91

+62.18 38.69% 5Y

Nasdaq, Closing price Tue, Feb 04 2025

-0.46 0.21%

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$21.80b
Enterprise Value	$20.19b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	6.09
P/S ratio (TTM) P/S ratio	6.57
P/B ratio (TTM) P/B ratio	6.92
Revenue growth (TTM) Revenue growth	50.46%
Revenue (TTM) Revenue	$3.32b
EBIT (operating result TTM) EBIT	$-872.57m
Free Cash Flow (TTM) Free Cash Flow	$-994.57m
Cash position	$2.71b
EPS (TTM) EPS	$-8.24
P/E forward	negative
P/S forward	5.87
EV/Sales forward	5.43
Short interest	2.64%

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Get Started for Free Today

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

28x Buy

90%

More details on Analyst Estimates Including Price Targets

31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	3,317 3,317	50% 50% 100%
- Direct Costs	660 660	55% 55% 20%
Gross Profit	2,656 2,656	49% 49% 80%
- Selling and Administrative Expenses	1,590 1,590	19% 19% 48%
- Research and Development Expense	1,794 1,794	8% 8% 54%
EBITDA	-727 -727	40% 40% -22%
- Depreciation and Amortization	145 145	78% 78% 4%
EBIT (Operating Income) EBIT	-873 -873	32% 32% -26%
Net Profit	-860 -860	10% 10% -26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BeiGene Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

about one month ago

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment ...

Neutral

Business Wire

●

about one month ago

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, ch...

Neutral

Business Wire

●

about 2 months ago

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2...

More BeiGene Ltd. Sponsored ADR News

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office	Cayman Islands
CEO	John Oyler
Employees	10,000
Founded	2010
Website	www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now